Price range: $54.00 through $86.00 / 10 Vials
Kisspeptin-10 is a potent truncated decapeptide derived from the Kiss1 gene product. Known as a fundamental regulator of the HPG (Hypothalamic-Pituitary-Gonadal) axis, it acts as a primary trigger for the onset of puberty and adult reproductive function. In research models, Kisspeptin-10 is utilized to stimulate the natural secretion of gonadotropins, offering a sophisticated method to modulate testosterone and estrogen levels by targeting the brain’s upstream hormonal control centers.
Amino Acid Sequence
Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
Molecular Formula
$C_{63}H_{78}N_{18}O_{13}$
Molecular Weight
1303.4 g/mol
PubChem CID
16132400
CAS Number
374675-21-5
Vial Size
3ml (or standard 2ml/5ml vials)
Contents
Lyophilized powder, white/off-white color
| Size | 10mg, 5mg |
|---|---|
| Mechanism of Action | GPR54 Receptor Agonist: Kisspeptin-10 binds with high affinity to the GPR54 (Kiss1R) receptors located on GnRH-secreting neurons in the hypothalamus. GnRH Secretion Trigger: Upon binding, it stimulates the pulsatile release of GnRH (Gonadotropin-Releasing Hormone), which then signals the pituitary gland. Downstream LH/FSH Elevation: The increase in GnRH leads to the secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), subsequently boosting endogenous testosterone or estrogen production. Restoration of Feedback Loops: Unlike exogenous hormones that may suppress the natural axis, Kisspeptin-10 research focuses on its ability to "restart" or optimize the body's own hormonal signaling pathways. |
| Storage & handling | Storage:Store the lyophilized vial in a cool, dry area protected from direct sunlight. |
All products on this site are for laboratory research, development, or analytical use only; they are NOT FOR HUMAN CONSUMPTION, medical, diagnostic, cosmetic, or veterinary applications.
These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat, or prevent any disease. Genixpep is not a compounding or outsourcing facility under sections 503A/503B of the FD&C Act.
